Key Points
-
B cell lymphomas show a range of extent and composition of tumour microenvironment components, partly reflecting tumour cell content and acquired genetic aberrations harboured by the lymphoma cells.
-
B cell lymphomas home to and co-opt the tumour microenvironment to derive survival and growth signals and to achieve escape from immune surveillance.
-
Tumour–microenvironment interactions are important contributors to both pathogenesis and prognosis of B cell lymphomas.
-
Some aspects of treatment resistance are mediated through tumour–microenvironment interactions, via factors secreted by stromal cells in response to lymphoma cells and cell adhesion-mediated drug resistance.
-
A fundamental understanding of tumour–microenvironment interactions underlies treatment strategies, including immune checkpoint blockade and separating lymphoma cells from their supportive microenvironment.
-
Future studies will include overlaying the genomic aberrations in the lymphoma cells on the composition of the tumour microenvironment and will aim to determine the functional consequences of these interactions.
Abstract
B cell lymphomas are cancers that arise from cells that depend on numerous highly orchestrated interactions with immune and stromal cells in the course of normal development. Despite the recent focus on dissecting the genetic aberrations within cancer cells, it has been increasingly recognized that tumour cells retain a range of dependence on interactions with the non-malignant cells and stromal elements that constitute the tumour microenvironment. A fundamental understanding of these interactions gives insight into the pathogenesis of most B cell lymphomas and, moreover, identifies novel therapeutic opportunities for targeting oncogenic pathways, both now and in the future.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Swerdlow, S. H. et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. (IARC Press, 2008).
Howlader N. et al. SEER Cancer Statistics Review, 1975–2010. National Cancer Institute. B ethesda, MD [online] (2013).
Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian CancerStatistics, Toronto, ON. Canadian Cancer Society(2013).
Shaffer, A. L. 3rd, Young, R. M. & Staudt, L. M. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 30, 565–610 (2012). This is a state-of-art review of B cell lymphoma pathogenesis.
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011). This updated review highlights the emerging role of the tumour microenvironment in cancer biology.
Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116–120 (2012).
Chung, Y. et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nature Med. 17, 983–988 (2011).
Linterman, M. A. et al. Foxp3+ follicular regulatory T cells control the germinal center response. Nature Med. 17, 975–982 (2011).
Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787–795 (2012).
Greaves, P. et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 122, 2856–2863 (2013).
Steidl, C., Connors, J. M. & Gascoyne, R. D. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J. Clin. Oncol. 29, 1812–1826 (2011).
Pals, S. T., de Gorter, D. J. & Spaargaren, M. Lymphoma dissemination: the other face of lymphocyte homing. Blood 110, 3102–3111 (2007).
Lopez-Giral, S. et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J. Leukoc. Biol. 76, 462–471 (2004).
Rehm, A. et al. Identification of a chemokine receptor profile characteristic for mediastinal large B-cell lymphoma. Int. J. Cancer 125, 2367–2374 (2009).
Rehm, A. et al. Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within secondary lymphoid organs. Blood 118, 1020–1033 (2011). This is an important animal model study demonstrating the importance of lymphoma cell homing to supportive microenvironments in disease establishment and progression.
Su, W., Spencer, J. & Wotherspoon, A. C. Relative distribution of tumour cells and reactive cells in follicular lymphoma. J. Pathol. 193, 498–504 (2001).
Oeschger, S., Bräuninger, A., Küppers, R. & Hansmann, M.-L. Tumor cell dissemination in follicular lymphoma. Blood 99, 2192–2198 (2002).
Schwickert, T. A., Alabyev, B., Manser, T. & Nussenzweig, M. C. Germinal center reutilization by newly activated B cells. J. Exp. Med. 206, 2907–2914 (2009).
Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25− T cells. Blood 110, 2537–2544 (2007).
Ai, W. Z. et al. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int. J. Cancer 124, 239–244 (2009).
Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 69, 5522–5530 (2009).
Lens, S. M. A. et al. Aberrant expression and reverse signalling of CD70 on malignant B cells. Br. J. Haematol. 106, 491–503 (1999).
Yang, Z. Z., Novak, A. J., Stenson, M. J., Witzig, T. E. & Ansell, S. M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107, 3639–3646 (2006).
Guilloton, F. et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood 119, 2556–2567 (2012).
The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89, 3909–3918 (1997).
Vega, F. et al. The stromal composition of malignant lymphoid aggregates in bone marrow: variations in architecture and phenotype in different B-cell tumours. Br. J. Haematol. 117, 569–576 (2002).
Rajnai, H. et al. Impact of the reactive microenvironment on the bone marrow involvement of follicular lymphoma. Histopathology 60, E66–E75 (2012).
Ghia, P., Granziero, L., Chilosi, M. & Caligaris-Cappio, F. Chronic B cell malignancies and bone marrow microenvironment. Semin. Cancer Biol. 12, 149–155 (2002).
Küppers, R. The biology of Hodgkin's lymphoma. Nature Rev. Cancer 9, 15–27 (2008).
Tweeddale, M. E. et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. Blood 69, 1307–1314 (1987).
Hussell, T., Isaacson, P. G., Crabtree, J. E. & Spencer, J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 342, 571–574 (1993).
Diehl, V. et al. Hodgkin's Disease: establishment and characterization of four in vitro cell lines. J. Cancer Res. Clin. 101, 111–124 (1981).
Umetsu, D. T., Esserman, L., Donlon, T. A., DeKruyff, R. H. & Levy, R. Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. J. Immunol. 144, 2550–2557 (1990).
Johnson, P. W. M. et al. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood 82, 1848–1857 (1993).
Lam, K. P., Kühn, R. & Rajewsky, K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90, 1073–1083 (1997).
Kraus, M., Alimzhanov, M. B., Rajewsky, N. & Rajewsky, K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igα/β heterodimer. Cell 117, 787–800 (2004).
Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573–586 (2009).
Küppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nature Rev. Cancer 5, 251–262 (2005).
Raffeld, M., Neckers, L., Longo, D. L. & Cossman, J. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma - escape from detection by anti-idiotype. N. Engl. J. Med. 312, 1653–1658 (1985).
Meeker, T. et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312, 1658–1665 (1985).
Sachen, K. L. et al. Self-antigen recognition by follicular lymphoma B cell receptors. Blood 120, 4182–4190 (2012).
Cha, S. C. et al. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J. Immunol. 190, 4887–4898 (2013).
Craig, V. J. et al. Gastric MALT lymphoma B cell express polyreactive, somatically mutated immunoglobulins. Blood 115, 581–591 (2010).
Bende, R. J. et al. Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J. Exp. Med. 201, 1229–1241 (2005).
Hadzidimitriou, A. et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 118, 3088–3095 (2011).
Zhu, D. et al. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood 99, 2562–2568 (2002). This is the first description of N -glycosylation motifs as an acquired somatic event in FL that later implicated the tumour microenvironment in lymphoma pathogenesis.
Coelho, V. et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc. Natl Acad. Sci. USA 107, 18587–18592 (2010).
McCann, K. J. et al. Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Mol. Immunol. 45, 1567–1572 (2008).
Roulland, S. et al. Early steps of follicular lymphoma pathogenesis. Adv. Immunol. 111, 1–46 (2011).
Stevenson, F. K. & Stevenson, G. T. Follicular lymphoma and the immune system: from pathogenesis to antibody therapy. Blood 119, 3659–3667 (2012).
Victora, G. D. & Nussenzweig, M. C. Germinal centers. Annu. Rev. Immunol. 30, 429–457 (2012).
Davis, R. E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88–92 (2010).
Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676–1679 (2008).
Ngo, V. N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115–119 (2010).
Rossi, D. et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J. Exp. Med. 209, 1537–1551 (2012).
Yan, Q. et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 97, 595–598 (2012).
Treon, S. P. et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N. Engl. J. Med. 367, 826–833 (2012).
Wang, J. Q., Jeelall, Y. S., Beutler, B., Horikawa, K. & Goodnow, C. C. Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance. J. Exp. Med. 211, 413–426 (2014).
Pangault, C. et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH-B cell axis. Leukemia 24, 2080–2089 (2010).
Calvo, K. R. et al. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood 112, 3818–3826 (2008).
Epron, G. et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia 26, 139–148 (2012).
Schiemann, B. et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111–2114 (2001).
Belnoue, E. et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111, 2755–2764 (2008).
Munari, F. et al. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood 117, 6612–6616 (2011).
Schwaller, J. et al. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia 21, 1324–1327 (2007).
Schwaller, J. et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 109, 331–338 (2007).
Ogden, C. A. et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J. Immunol. 174, 3015–3023 (2005).
Buske, C. et al. In vitro activation of low-grade non-Hodgkin's lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand. Leukemia 11, 1862–1867 (1997).
Lwin, T. et al. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia 23, 170–177 (2009).
Amé-Thomas, P. et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 109, 693–702 (2007).
Medina, D. J. et al. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica 97, 1255–1263 (2012).
Dierks, C. et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nature Med. 13, 944–951 (2007).
Singh, R. R. et al. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 24, 1025–1036 (2010).
Kim, J. E. et al. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod. Pathol. 22, 1312–1320 (2009).
Riemersma, S. A. et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96, 3569–3577 (2000).
Steidl, C. et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377–381 (2011).
Wilkinson, S. T. et al. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood 119, 1459–1467 (2011).
Rimsza, L. M. et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103, 4251–4258 (2004).
Challa-Malladi, M. et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 20, 728–740 (2011).
Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genet. 43, 830–837 (2011).
Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476, 298–303 (2011). References 80 and 81, among others, established the landscape of recurrent mutations in DLBCL and revealed numerous mutations that influence tumour–microenvironment interactions.
Rosenwald, A. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851–862 (2003).
Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268–3277 (2010).
Steidl, C. et al. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 116, 418–427 (2010).
Diepstra, A. et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 71, 219–226 (2008).
Verbeke, C. S., Wenthe, U., Grobholz, R. & Zentgraf, H. Fas ligand expression in Hodgkin lymphoma. Am. J. Surg. Pathol. 25, 388–394 (2001).
Ramsay, A. G. et al. Follicular lymphoma cell induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 114, 4713–4720 (2009).
Kiaii, S. et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J. Clin. Oncol. 31, 2654–2661 (2013).
Yang, Z. Z., Novak, A. J., Ziesmer, S. C., Witzig, T. E. & Ansell, S. M. Attenuation of CD8+ T-cell function by CD4+CD25+ regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 66, 10145–10152 (2006).
Amé-Thomas, P. et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 26, 1053–1063 (2012).
Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51 (2010).
Sánchez-Aguilera, A. et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108, 662–668 (2006).
Chetaille, B. et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113, 2765–2775 (2009).
Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 362, 875–885 (2010).
Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313–2323 (2008).
Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med. 351, 2159–2169 (2004). References 94–96 highlight the role of the microenvironment in treatment outcome in B cell lymphomas.
Álvaro, T. et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11, 1467–1473 (2005).
Kelley, T. W., Pohlman, B., Elson, P. & Hsi, E. D. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am. J. Clin. Pathol. 128, 958–965 (2007).
Bingle, L., Brown, N. J. & Lewis, C. E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196, 254–265 (2002).
Fridman, W. H., Pagès, F., Sautès-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nature Rev. Cancer 12, 298–306 (2012).
Sánchez-Espiridión, B. et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 116, e12–e17 (2010).
Scott, D. W. et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J. Clin. Oncol. 31, 692–700 (2013).
Meyer, P. N. et al. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am. J. Clin. Pathol. 135, 54–61 (2011).
Cardesa-Salzmann, T. M. et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 96, 996–1001 (2011).
de Jong, D. et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 94, 70–77 (2009).
Gribben, J. G. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr. Opin. Oncol. 22, 424–430 (2010).
Kridel, R., Sehn, L. H. & Gascoyne, R. D. Pathogenesis of follicular lymphoma. J. Clin. Invest. 122, 3424–3431 (2012).
Sander, B. et al. The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. Haematologica 99, 715–725 (2014).
Cerhan, J. R. et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 109, 5439–5446 (2007).
Habermann, T. M. et al. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 112, 2694–2702 (2008).
Ghesquieres, H. et al. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. Cytokine 64, 523–531 (2013).
McMillin, D. W., Negri, J. M. & Mitsiades, C. S. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nature Rev. Drug Discov. 12, 217–228 (2013).
Lwin, T. et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-κB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 21, 1521–1531 (2007).
Kurtova, A. V., Tamayo, A. T., Ford, R. J. & Burger, J. A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113, 4604–4613 (2009).
Mraz, M. et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br. J. Haematol. 155, 53–64 (2011).
Lwin, T. et al. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood 116, 5228–5236 (2010).
Lwin, T. et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J. Clin. Invest. 123, 4612–4626 (2013).
Lwin, T. et al. Cell adhesion induces p27 Kip 1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 110, 1631–1638 (2007). References 116–118 describe the mechanisms by which direct interactions between lymphoma cells and stromal cells in the microenvironment lead to drug resistance.
Wotherspoon, A. C. et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342, 575–577 (1993). This paper, along with earlier papers showing the presence of H. pylori in gastric MALT lymphoma, established the link between pathogens in the microenvironment, the pathogenesis of MALT lymphoma and therapy.
Brody, J., Kohrt, H., Marabelle, A. & Levy, R. Active and passive immunotherapy for lymphoma: proving principles and improving results. J. Clin. Oncol. 29, 1864–1875 (2011).
Hegde, G. V. et al. Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling. Int. J. Cancer 131, 2951–2960 (2012).
Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31, 88–94 (2013).
Pallasch, C. P. et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 156, 590–602 (2014). This paper describes the use of autochthonous mouse models to investigate methods by which drug resistance associated with the tumour microenvironment may be overcome.
Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
Ribatti, D., Nico, B., Ranieri, G., Specchia, G. & Vacca, A. The role of angiogenesis in human non-Hodgkin lymphomas. Neoplasia 15, 231–238 (2013).
Gratzinger, D. et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am. J. Pathol. 170, 1362–1369 (2007).
Gratzinger, D. et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest. 88, 38–47 (2008).
Gratzinger, D. et al. Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br. J. Haematol. 148, 235–244 (2010).
Stopeck, A. T. et al. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 120, 1210–1217 (2012).
Ruan, J. et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 121, 5192–5202 (2013).
O'Callaghan, K. et al. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 119, 1717–1725 (2012).
Hu, Y. et al. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists. Leuk. Lymphoma 53, 130–138 (2012).
Burger, J. A. & Montserrat, E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 121, 1501–1509 (2013).
Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507–516 (2013).
Chang, B. Y. et al. Egress of CD19+CD5+ cells into the peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 122, 2412–2424 (2013).
Okosun, J. et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genet. 46, 176–181 (2013).
Pasqualucci, L. et al. Genetics of follicular lymphoma transformation. Cell Rep. 6, 130–140 (2014).
von Andrian, U. H. & Mempel, T. R. Homing and cellular traffic in lymph nodes. Nature Rev. Immunol. 3, 867–878 (2003).
Mueller, S. N. & Germain, R. N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nature Rev. Immunol. 9, 618–629 (2009).
Batista, F. D. & Harwood, N. E. The who, how and where of antigen presentation to B cells. Nature Rev. Immunol. 9, 15–27 (2009).
McHeyzer-Williams, M., Okitsu, S., Wang, N. & McHeyzer-Williams, L. Molecular programming of B cell memory. Nature Rev. Immunol. 12, 24–34 (2012).
Schwickert, T. A. et al. A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J. Exp. Med. 208, 1243–1252 (2011).
Calado, D. P. et al. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nature Immunol. 13, 1092–1100 (2012).
Dominguez-Sola, D. et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nature Immunol. 13, 1083–1091 (2012).
Victora, G. D. et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 143, 592–605 (2010).
Gitlin, A. D., Shulman, Z. & Nussenzweig, M. C. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509, 637–640 (2014).
Allen, C. D. et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nature Immunol. 5, 943–952 (2004).
Jares, P., Colomer, D. & Campo, E. Molecular pathogenesis of mantle cell lymphoma. J. Clin. Invest. 122, 3416–3423 (2012).
Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000). This paper describes using the similarity of gene expression profiles of lymphoma cells to a physiological counterpart to assign the cell of origin.
Victora, G. D. et al. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood 120, 2240–2248 (2012).
Wotherspoon, A. C., Ortiz-Hidalgo, C., Falzon, M. R. & Isaacson, P. G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338, 1175–1176 (1991).
Hussell, T., Isaacson, P. G., Crabtree, J. E. & Spencer, J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J. Pathol. 178, 122–127 (1996).
Isaacson, P. G. & Du, M.-Q. MALT lymphoma: from morphology to molecules. Nature Rev. Cancer 4, 644–653 (2004).
Lohr, J. G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109, 3879–3884 (2012).
Zhang, J. et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl Acad. Sci. USA 110, 1398–1403 (2013).
Green, M. R. et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 121, 1604–1611 (2013).
Bea, S. et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl Acad. Sci. USA 110, 18250–18255 (2013).
Kiel, M. J. et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J. Exp. Med. 209, 1553–1565 (2012).
Richter, J. et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nature Genet. 44, 1316–1320 (2012).
Love, C. et al. The genetic landscape of mutations in Burkitt lymphoma. Nature Genet. 44, 1321–1325 (2012).
Dang, N. H. et al. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J. Clin. Oncol. 22, 4095–4102 (2004).
Kuzel, T. M. et al. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497. Leuk. Lymphoma 48, 2397–2402 (2007).
Dang, N. H. et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br. J. Haematol. 138, 502–505 (2007).
Ansell, S. M. et al. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma. Leukemia 26, 1046–1052 (2012).
Ansell, S. M. et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clin. Cancer Res. 12, 6056–6063 (2006).
Ansell, S. M. et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15, 6446–6453 (2009).
Bashey, A. et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113, 1581–1588 (2009).
O'Mahony, D. et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin. Cancer Res. 13, 958–964 (2007).
Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044–3051 (2008).
Armand, P. et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31, 4199–4206 (2013).
Westin, J. R. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69–77 (2014).
Younes, A. et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119, 4123–4128 (2012).
Kasamon, Y. L. et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 119, 4129–4132 (2012).
Ansell, S. M. et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 14, 1105–1110 (2008).
Wiernik, P. H. et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 26, 4952–4957 (2008).
Habermann, T. M. et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 145, 344–349 (2009).
Witzig, T. E. et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 5404–5409 (2009).
Witzig, T. E. et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann. Oncol. 22, 1622–1627 (2011).
Zinzani, P. L. et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann. Oncol. 24, 2892–2897 (2013).
Eve, H. E. et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br. J. Haematol. 159, 154–163 (2012).
Goy, A. et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J. Clin. Oncol. 31, 3688–3695 (2013).
Kiesewetter, B. et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica 98, 353–356 (2013).
Fehniger, T. A. et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 118, 5119–5125 (2011).
Zaja, F. et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 97, 416–422 (2012).
Wang, M. et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 13, 716–723 (2012).
Zinzani, P. L. et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin. Lymphoma Myeloma Leuk. 11, 462–466 (2011).
Wang, M. et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27, 1902–1909 (2013).
Ahmadi, T. et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 120, 222–228 (2014).
Nowakowski, G. S. et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 25, 1877–1881 (2011).
Tilly, H. et al. Phase Ib study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 27, 252–255 (2013).
Chiappella, A. et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica 98, 1732–1738 (2013).
Stopeck, A. T. et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk. Lymphoma 50, 728–735 (2009).
Ruan, J. et al. Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clin. Lymphoma Myeloma Leuk. 14, 107–113 (2014).
Booman, M. et al. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma. Clin. Cancer Res. 12, 2698–2705 (2006).
Braggio, E. et al. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin. Cancer Res. 17, 4245–4253 (2011).
Sung, C. O. et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 117, 1291–1300 (2011).
Twa, D. D. et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 123, 2062–2065 (2014).
Cheung, K. J. J. et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosome Cancer 49, 669–681 (2010).
Cheung, K. J. et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 70, 9166–9174 (2010).
Morin, R. D. et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole genome sequencing. Blood 122, 1256–1265 (2013).
Green, J. A. et al. The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement. Nature Immunol. 12, 672–680 (2011).
Cattoretti, G. et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res. 69, 8686–8692 (2009).
Oricchio, E. et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147, 554–564 (2011).
Acknowledgements
The authors receive research support from the Terry Fox Research Institute, Vancouver, Canada, the Canadian Institutes of Health Research, Genome Canada and Genome British Columbia and the Lymphoma Research Foundation US. The authors apologize to the numerous colleagues whose important contributions could not be included in this Review owing to space limitations.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Glossary
- Lymphoid structures
-
These include the primary lymphoid organs (bone marrow and thymus), secondary or peripheral lymphoid organs (lymph nodes, spleen and mucosa-associated lymphoid tissue) and the tertiary lymphoid organs, which develop at sites of infection and chronic stimulation of the immune system.
- Sclerosis
-
A hardening or thickening of the tissue owing to excessive growth of fibrous connective tissue.
- Reactive germinal centres
-
Physiological germinal centres that are produced in response to an antigenic stimulus.
- Follicular dendritic cells
-
(FDCs). Stromal cells of mesenchymal origin that are located in the B cell follicles of secondary lymphoid organs, where they present intact antigen to B cells undergoing the germinal centre reaction, thereby contributing to affinity maturation.
- Follicular T helper cells
-
(TFH cells). A distinct set of antigen-experienced CD4+ T helper cells that are focused in the germinal centre and contribute to the affinity maturation of B cells.
- Hodgkin Reed–Sternberg cells
-
(HRS cells). The pathognomonic neoplastic B cells of classical Hodgkin's lymphoma with characteristic morphology, immunophenotype and genetic alterations, including classic binucleate cells (Reed–Sternberg cells) and mononuclear variants (Hodgkin cells).
- Tingible-body macrophages
-
A type of macrophage that is found physiologically in germinal centres, with their appearance related to the staining characteristics of phagocytosed debris from apoptotic cells.
- Follicular regulatory T cells
-
(TFR cells). A set of regulatory T cells that are CXC-chemokine receptor 5 (CXCR5)+ and BCL-6+, localized to germinal centres and prevent excessive germinal centre reactions.
- Co-stimulation
-
Appropriate activation of T cells involves binding of the antigen by the T cell receptor, together with other 'co-stimulatory' signals from the cell presenting the antigen.
- Tumour-associated macrophage
-
A cell derived from circulating monocytes or tissue-resident macrophages that is found in close proximity to tumours or within them.
- Paratrabecular
-
Pertaining to being located adjacent to the trabeculae of bone in the bone marrow.
- Fibroblastic reticular cells
-
(FRCs). Stromal cells that make up the scaffold of the T cell zone of secondary lymphoid organs; they direct lymphocyte trafficking within the organs and they present antigens.
- Autochthonous animal models
-
Models in which the tumours arise in organs that are typically infiltrated by the cancer, potentially allowing the impact of interactions between the microenvironment of these organs and the tumour cells to be examined.
- Anti-idiotype treatment
-
This treatment uses monoclonal antibodies that specifically recognize unique determinants in the variable regions of immunoglobulins on the tumour cells.
- Somatic hypermutation
-
(SHM). This process is mediated by the enzyme activation-induced (cytidine) deaminase (AID), occurring in B cells in the germinal centres, whereby the variable regions of the immunoglobulin genes are mutated, allowing for an increased specificity of antibody for antigen.
- Antigen-presenting cells
-
These cells, which include dendritic cells, macrophages and some B cells, mediate cellular immune responses by presenting antigen in the context of major histocompatibility complex class II to T cells.
- Cytotoxic T lymphocytes
-
(CTLs). CD8+ T cells that kill cells on the basis of the presentation by that cell of specific antigen recognized by the T cell receptor of the cytotoxic T cell.
- Natural killer cells
-
(NK cells). A type of cytotoxic lymphocyte (part of the innate immune system) that has a role in killing tumour cells and virally infected cells without the requirement for antigen presentation in the context of major histocompatibility complex class I.
- Immune checkpoint blockade
-
A strategy that involves blockade of the inhibitory ligands and/or receptors that modify the response of T cells to antigen presented to the T cell receptor, thereby inhibiting T cell activation and impairing T cell function.
Rights and permissions
About this article
Cite this article
Scott, D., Gascoyne, R. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14, 517–534 (2014). https://doi.org/10.1038/nrc3774
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3774